Semin intervent Radiol 2015; 32(04): 388-397
DOI: 10.1055/s-0035-1564704
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Yttrium-90 Radioembolization of Hepatocellular Carcinoma–Performance, Technical Advances, and Future Concepts

Christopher Molvar
1  Section of Vascular and Interventional Radiology, Department of Radiology, Loyola University Medical Center, Maywood, Illinois
,
Robert Lewandowski
2  Division of Interventional Oncology, Section of Interventional Radiology, Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
10 November 2015 (online)

Abstract

Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 (90Y) radioembolization. This review will showcase the performance of 90Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.